Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Manic Fringe deficiency imposes Jagged1 addiction to intestinal tumor cells.

López-Arribillaga E, Rodilla V, Colomer C, Vert A, Shelton A, Cheng JH, Yan B, Gonzalez-Perez A, Junttila MR, Iglesias M, Torres F, Albanell J, Villanueva A, Bigas A, Siebel CW, Espinosa L.

Nat Commun. 2018 Jul 31;9(1):2992. doi: 10.1038/s41467-018-05385-0.

2.

IFN-γ-induced chemokines are required for CXCR3-mediated T cell recruitment and anti-tumor efficacy of anti-HER2/CD3 bispecific antibody.

Li J, Ybarra R, Mak J, Herault A, De Almeida P, Arrazate A, Ziai J, Totpal K, Junttila MR, Walsh KB, Junttila TT.

Clin Cancer Res. 2018 Jun 27. pii: clincanres.1139.2018. doi: 10.1158/1078-0432.CCR-18-1139. [Epub ahead of print]

PMID:
29950350
3.

Tumor Elastography and Its Association with Collagen and the Tumor Microenvironment.

Riegler J, Labyed Y, Rosenzweig S, Javinal V, Castiglioni A, Dominguez CX, Long JE, Li Q, Sandoval W, Junttila MR, Turley SJ, Schartner J, Carano RAD.

Clin Cancer Res. 2018 Sep 15;24(18):4455-4467. doi: 10.1158/1078-0432.CCR-17-3262. Epub 2018 May 24.

PMID:
29798909
4.

Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors.

Merchant M, Moffat J, Schaefer G, Chan J, Wang X, Orr C, Cheng J, Hunsaker T, Shao L, Wang SJ, Wagle MC, Lin E, Haverty PM, Shahidi-Latham S, Ngu H, Solon M, Eastham-Anderson J, Koeppen H, Huang SA, Schwarz J, Belvin M, Kirouac D, Junttila MR.

PLoS One. 2018 Jan 25;13(1):e0192059. doi: 10.1371/journal.pone.0192059. eCollection 2018.

5.

Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous.

Chung WJ, Daemen A, Cheng JH, Long JE, Cooper JE, Wang BE, Tran C, Singh M, Gnad F, Modrusan Z, Foreman O, Junttila MR.

Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E10947-E10955. doi: 10.1073/pnas.1708391114. Epub 2017 Dec 4.

6.

Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors.

Merchant M, Moffat J, Schaefer G, Chan J, Wang X, Orr C, Cheng J, Hunsaker T, Shao L, Wang SJ, Wagle MC, Lin E, Haverty PM, Shahidi-Latham S, Ngu H, Solon M, Eastham-Anderson J, Koeppen H, Huang SA, Schwarz J, Belvin M, Kirouac D, Junttila MR.

PLoS One. 2017 Oct 5;12(10):e0185862. doi: 10.1371/journal.pone.0185862. eCollection 2017. Erratum in: PLoS One. 2018 Jan 25;13(1):e0192059.

7.

Transcription factor Etv5 is essential for the maintenance of alveolar type II cells.

Zhang Z, Newton K, Kummerfeld SK, Webster J, Kirkpatrick DS, Phu L, Eastham-Anderson J, Liu J, Lee WP, Wu J, Li H, Junttila MR, Dixit VM.

Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3903-3908. doi: 10.1073/pnas.1621177114. Epub 2017 Mar 28.

8.

Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer.

Junttila MR, Mao W, Wang X, Wang BE, Pham T, Flygare J, Yu SF, Yee S, Goldenberg D, Fields C, Eastham-Anderson J, Singh M, Vij R, Hongo JA, Firestein R, Schutten M, Flagella K, Polakis P, Polson AG.

Sci Transl Med. 2015 Nov 18;7(314):314ra186. doi: 10.1126/scitranslmed.aac7433.

PMID:
26582901
9.

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.

Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL.

J Clin Oncol. 2015 Dec 20;33(36):4284-92. doi: 10.1200/JCO.2015.62.8719. Epub 2015 Nov 2.

10.

Translational value of mouse models in oncology drug development.

Gould SE, Junttila MR, de Sauvage FJ.

Nat Med. 2015 May;21(5):431-9. doi: 10.1038/nm.3853.

PMID:
25951530
11.

Castration-resistant Lgr5(+) cells are long-lived stem cells required for prostatic regeneration.

Wang BE, Wang X, Long JE, Eastham-Anderson J, Firestein R, Junttila MR.

Stem Cell Reports. 2015 May 12;4(5):768-79. doi: 10.1016/j.stemcr.2015.04.003. Epub 2015 Apr 30.

12.

Quantification of Tumor Burden in a Genetically Engineered Mouse Model of Lung Cancer by Micro-CT and Automated Analysis.

Barck KH, Bou-Reslan H, Rastogi U, Sakhuja T, Long JE, Molina R, Lima A, Hamilton P, Junttila MR, Johnson L, Carano RA.

Transl Oncol. 2015 Apr;8(2):126-35. doi: 10.1016/j.tranon.2015.03.003.

13.

Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.

Junttila MR, Devasthali V, Cheng JH, Castillo J, Metcalfe C, Clermont AC, Otter DD, Chan E, Bou-Reslan H, Cao T, Forrest W, Nannini MA, French D, Carano R, Merchant M, Hoeflich KP, Singh M.

Mol Cancer Ther. 2015 Jan;14(1):40-7. doi: 10.1158/1535-7163.MCT-14-0030. Epub 2014 Nov 5.

14.

Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.

Junttila TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, Wang BE, Li Y, Mathieu M, Li G, Young J, Luis E, Lewis Phillips G, Stefanich E, Spiess C, Polson A, Irving B, Scheer JM, Junttila MR, Dennis MS, Kelley R, Totpal K, Ebens A.

Cancer Res. 2014 Oct 1;74(19):5561-71. doi: 10.1158/0008-5472.CAN-13-3622-T. Epub 2014 Sep 16.

15.

BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues.

Muthalagu N, Junttila MR, Wiese KE, Wolf E, Morton J, Bauer B, Evan GI, Eilers M, Murphy DJ.

Cell Rep. 2014 Sep 11;8(5):1347-53. doi: 10.1016/j.celrep.2014.07.057. Epub 2014 Aug 28.

16.

Lymph node-independent liver metastasis in a model of metastatic colorectal cancer.

Enquist IB, Good Z, Jubb AM, Fuh G, Wang X, Junttila MR, Jackson EL, Leong KG.

Nat Commun. 2014 Mar 26;5:3530. doi: 10.1038/ncomms4530.

PMID:
24667486
17.

Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors.

Croci DO, Cerliani JP, Dalotto-Moreno T, Méndez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, Toscano MA, Caramelo JJ, García-Vallejo JJ, Ouyang J, Mesri EA, Junttila MR, Bais C, Shipp MA, Salatino M, Rabinovich GA.

Cell. 2014 Feb 13;156(4):744-58. doi: 10.1016/j.cell.2014.01.043.

18.

Influence of tumour micro-environment heterogeneity on therapeutic response.

Junttila MR, de Sauvage FJ.

Nature. 2013 Sep 19;501(7467):346-54. doi: 10.1038/nature12626. Review.

PMID:
24048067
19.

Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment.

Phan VT, Wu X, Cheng JH, Sheng RX, Chung AS, Zhuang G, Tran C, Song Q, Kowanetz M, Sambrone A, Tan M, Meng YG, Jackson EL, Peale FV, Junttila MR, Ferrara N.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6079-84. doi: 10.1073/pnas.1303302110. Epub 2013 Mar 25.

20.

Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.

Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemelä M, Khanna A, Chan EK, Kähäri VM, Kellokumpu-Lehtinen PL, Sansom OJ, Evan GI, Junttila MR, Ryan KM, Marine JC, Joensuu H, Westermarck J.

Cancer Discov. 2013 Feb;3(2):182-97. doi: 10.1158/2159-8290.CD-12-0292. Epub 2013 Jan 10.

21.

Selective activation of p53-mediated tumour suppression in high-grade tumours.

Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F, Brown Swigart L, Pham DM, Seo Y, Evan GI, Martins CP.

Nature. 2010 Nov 25;468(7323):567-71. doi: 10.1038/nature09526.

22.

p53--a Jack of all trades but master of none.

Junttila MR, Evan GI.

Nat Rev Cancer. 2009 Nov;9(11):821-9. doi: 10.1038/nrc2728. Epub 2009 Sep 24. Review.

PMID:
19776747
23.

Acute overexpression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/beta-catenin pathway activation.

Finch AJ, Soucek L, Junttila MR, Swigart LB, Evan GI.

Mol Cell Biol. 2009 Oct;29(19):5306-15. doi: 10.1128/MCB.01745-08. Epub 2009 Jul 27.

24.

MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.

Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimäki A.

J Natl Cancer Inst. 2009 Jun 3;101(11):793-805. doi: 10.1093/jnci/djp103. Epub 2009 May 26.

PMID:
19470954
25.

PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma.

Puustinen P, Junttila MR, Vanhatupa S, Sablina AA, Hector ME, Teittinen K, Raheem O, Ketola K, Lin S, Kast J, Haapasalo H, Hahn WC, Westermarck J.

Cancer Res. 2009 Apr 1;69(7):2870-7. doi: 10.1158/0008-5472.CAN-08-2760. Epub 2009 Mar 17.

26.

Distinct thresholds govern Myc's biological output in vivo.

Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L, Evan GI.

Cancer Cell. 2008 Dec 9;14(6):447-57. doi: 10.1016/j.ccr.2008.10.018.

27.

Mechanisms of MYC stabilization in human malignancies.

Junttila MR, Westermarck J.

Cell Cycle. 2008 Mar 1;7(5):592-6. Epub 2007 Dec 29. Review. Erratum in: Cell Cycle. 2009 Feb 1;8(3):507.

PMID:
18256542
28.

Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival.

Junttila MR, Li SP, Westermarck J.

FASEB J. 2008 Apr;22(4):954-65. Epub 2007 Nov 26. Review.

PMID:
18039929
29.

CIP2A inhibits PP2A in human malignancies.

Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grènman R, Kast J, Kallunki T, Sears R, Kähäri VM, Westermarck J.

Cell. 2007 Jul 13;130(1):51-62.

30.

p38alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells.

Junttila MR, Ala-Aho R, Jokilehto T, Peltonen J, Kallajoki M, Grenman R, Jaakkola P, Westermarck J, Kähäri VM.

Oncogene. 2007 Aug 9;26(36):5267-79. Epub 2007 Mar 5.

PMID:
17334397
31.

Single-step Strep-tag purification for the isolation and identification of protein complexes from mammalian cells.

Junttila MR, Saarinen S, Schmidt T, Kast J, Westermarck J.

Proteomics. 2005 Apr;5(5):1199-203.

PMID:
15761952

Supplemental Content

Loading ...
Support Center